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Abstract
Introduction: Altered pharmacokinetics (PK) in critically ill patients can result in insufficient serum β-lactam 
concentrations when standard dosages are administered. Previous studies on β-lactam PK have generally excluded the 
most severely ill patients, or were conducted during the steady-state period of treatment. The aim of our study was to 
determine whether the first dose of piperacillin-tazobactam, ceftazidime, cefepime, and meropenem would result in 
adequate serum drug concentrations in patients with severe sepsis and septic shock.
Methods: Open, prospective, multicenter study in four Belgian intensive care units. All consecutive patients with a 
diagnosis of severe sepsis or septic shock, in whom treatment with the study drugs was indicated, were included. 
Serum concentrations of the antibiotics were determined by high-pressure liquid chromatography (HPLC) before and 
1, 1.5, 4.5 and 6 or 8 hours after administration.
Results: 80 patients were treated with piperacillin-tazobactam (n = 27), ceftazidime (n = 18), cefepime (n = 19) or 
meropenem (n = 16). Serum concentrations remained above 4 times the minimal inhibitory concentration (T > 4 × 
MIC), corresponding to the clinical breakpoint for Pseudomonas aeruginosa defined by the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST), for 57% of the dosage interval for meropenem (target MIC = 8 μg/mL), 
45% for ceftazidime (MIC = 32 μg/mL), 34% for cefepime (MIC = 32 μg/mL), and 33% for piperacillin-tazobactam (MIC = 
64 μg/mL). The number of patients who attained the target PK profile was 12/16 for meropenem (75%), 5/18 for 
ceftazidime (28%), 3/19 (16%) for cefepime, and 12/27 (44%) for piperacillin-tazobactam.
Conclusions: Serum concentrations of the antibiotic after the first dose were acceptable only for meropenem. 
Standard dosage regimens for piperacillin-tazobactam, ceftazidime and cefepime may, therefore, be insufficient to 
empirically cover less susceptible pathogens in the early phase of severe sepsis and septic shock.
Introduction
Severe sepsis and septic shock remain a major cause of
morbidity and mortality in medical and surgical ICUs [1].
Although early and appropriate antibacterial therapy is
considered a priority in the management of patients with
sepsis [2,3], there is evidence that optimizing antibiotic
dosage regimens to achieve therapeutic concentrations in
the blood and at the site of infection is equally important
[4].
Antibiotherapy in critically ill septic patients usually
consists of a broad-spectrum β-lactam combined with a
glycopeptide and/or an aminoglycoside [5]. These drugs
cover a large variety of pathogens and can be empirically
used for Gram-negative bacterial infections, including
those caused by Pseudomonas aeruginosa. The activity of
β-lactams is predominantly time-dependent and requires
serum and tissue antibiotic concentrations above the
minimal inhibitory concentration (MIC) of the pathogen
to achieve adequate bacterial killing [6]. This effect is
independent of peak levels and there is no significant
post-antibiotic effect, except for carbapenems. Clinical
data suggest that maximum killing of bacteria occurs
when serum concentrations are maintained above the
MIC of the causative pathogens for extended periods
[7,8]; this may be especially appropriate in patients with
compromised host-defences, including critically ill
patients [9,10]. However, in conventional bolus dosing
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regimens, serum β-lactam concentrations may fall to low
levels between doses [11,12], with potentially negative
effects on clinical response and emergence of resistances.
Antibiotic dosage regimens used in ICU pa tients are
often based on pharmacokinetic (PK) data that were
obtained in healthy volunteers or less severely ill patients.
Moreover, they rarely take into account the dynamic
changes of the septic process that can reduce the efficacy
of anti-infective treatments and consequently affect
patient outcomes [6]. During severe sepsis and septic
shock, increased volume of distribution (Vd) and cardiac
output can reduce serum drug concentrations, whereas
decreased protein binding and end-organ dysfunction
induce higher antibiotic levels [13]. Optimizing antibiotic
dosage strategy should involve PK parameters, but thera-
peutic drug monitoring is necessary in septic patients
because large inter-individual PK variations make it diffi-
cult to predict antibiotic levels [14]. As previous PK stud-
ies on β-lactams in ICU patients have excluded the most
severely ill patients or were conducted in the steady-state
period of treatment [15-17], the main objective of this
study was to determine whether the currently recom-
mended first dose of four broad-spectrum β-lactams
(piperacillin-tazobactam, ceftazidime, cefepime, and
meropenem) provide adequate plasma concentrations in
critically ill septic patients in the ICU. We also tried to
determine whether clinical or hemodynamic parameters
could affect the PK profile of these drugs during such
severe infections.
Materials and methods
Study design, patients, antibiotic treatment and data 
collection
This was a prospective, multicenter, observational study
performed in four Departments of Intensive Care in Bel-
gium (at the St-Luc Hospital, Erasme Hospital, and UZ-
VUB in Brussels and St Pierre Hospital in Ottignies). The
study protocol was approved by the university ethics
committees of the different hospitals. Before enrolment,
written consent was obtained from the patient or their
nearest relative.
All patients admitted to one of the four ICUs between
January 2005 and July 2006 were considered for inclusion.
Inclusion criteria were a diagnosis of severe sepsis or sep-
tic shock [18], either at admission or during the ICU stay,
and treatment with a broad-spectrum β-lactam antibiotic
(ceftazidime, cefepime, piperacillin-tazobactam, or mero-
penem). Patients meeting one of the following criteria
were excluded: age less than 18 years or more than 85
years; pregnancy or lactation; previous administration of
any of the investigated antibiotics; chronic renal failure
requiring dialysis; or allergy to any of the investigated
antibiotics. The study period was limited to the first 24
hours of antibiotherapy.
Administration of the four β-lactams was made accord-
ing to local guidelines. These drugs are generally used in
the participating centers to treat hospital- or ICU-
acquired infections or in the case of community-acquired
infection when a more-resistant pathogen may be
involved (recent hospitalization or antibiotic therapy,
previous colonization by more resistant strain). Piperacil-
lin-tazobactam was preferred as first-line therapy in cases
of proven or suspected intra-abdominal infections. Cef-
tazidime and cefepime was used as first-line therapy in
other cases. Meropenem was used as second-line therapy
(i.e. failure of piperacillin-tazobactam or cephalosporins)
or in case of suspected or previous colonization by
extended spectrum beta-lactamase Gram-negative bacte-
ria.
In all study patients, demographics, pre-existing
chronic diseases, admission diagnosis and biological data
were collected in institutional databases. The severity of
illness of each patient was characterized using the Acute
Physiology and Chronic Health Evaluation (APACHE) II
[19] and sequential organ failure assessment (SOFA) [20]
scores determined on the first day of antibiotic treatment.
Creatinine clearance (CrCl) was calculated using a stan-
dard formula [21]. Treatment of patients with cate-
cholamines, mechanical ventilation, hemofiltration or
hemodialysis was recorded, as was length of ICU and
hospital stay, overall mortality, and cause of death. Hemo-
dynamic data were collected at baseline, and 8 and 24
hours after the start of the protocol.
Analytic method for β-lactams
All the patients included in the study received a first dose
of 2 g ceftazidime or cefepime, 4 g/0.5 g piperacillin-
tazobactam, or 1 g meropenem. The usual daily doses of
these antibiotics and dose adjustments for renal function
are presented in Additional file 1. All the patients also
received amikacin and the two antibiotics were adminis-
tered simultaneously over 30 minutes using an infusion
pump. Blood samples of 5 mL were collected without
anticoagulant immediately before the infusion (0 hour)
and 1, 1.5, 4.5, and 6 or 8 hours (depending on the fre-
quency of administration of the β-lactam) thereafter;
these blood-draw time points were chosen as they belong
to the elimination phase of all four antibiotics. The exact
sampling time was recorded by the nursing or medical
staff. Blood samples were centrifuged at 4000 g for 10
minutes after blood clotting. To allow for possible drug
instability at room temperature, serum samples were
stored at -80°C until analysis.
All antibiotic quantitative analyses were performed in a
centralized reference laboratory (St Luc Hospital).
Importantly, as the PK of piperacillin and tazobactam are
highly correlated [22], we only measured piperacillin lev-
els. Serum β-lactam concentrations were determined byTaccone et al. Critical Care 2010, 14:R126
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high-performance liquid chromatography with diode
array detection. The intravenous antibiotic formulations
were reconstituted according to the manufacturers' rec-
ommendations and diluted in water in order to reach
stock solution aliquots of 1 mg/mL, stored at -20°C.
Before each assay, a fresh calibration curve was prepared
from the stock solution and blank serum at the following
concentrations: 0.75, 1, 2, 5, 10, 25, and 50 μg/mL for pip-
eracillin-tazobactam; 5, 10, 25, 50, and 100 μg/mL for cef-
tazidime; 0.1, 0.25, 0.5, 1, 5, 10, 25, and 50 μg/mL for
cefepime or meropenem. The calibration and liquid-liq-
u i d  e x t r a c t i o n  p r o c e d u r e s  a s  w e l l  a s  c h r o m a t o g r a p h i c
conditions have been described previously [23]. The vali-
dation of the four analytical methods was performed over
a three-day period with five calibration curves per day
(i.e., 15 serum samples per concentration level). All meth-
ods were validated according to the published acceptance
criteria for specificity, linearity, accuracy, precision
(intra-day (repeatability), inter-day (intermediate preci-
sion)) and sensitivity (limit of detection (LOD) and limit
of quantification (LOQ)). Specificity was determined by
the ability to identify the β-lactam from its characteristic
retention time and ultraviolet spectrum, and the fine res-
olution of its chromatographic peak. The linearity of the
calibration curve was demonstrated by a significant linear
regression analysis, with a determination coefficient (r2)
more than 0.99. Accuracy was expressed as the percent
deviation of the mean observed concentration from the
theoretical value, which should not exceed 15%, except at
the LOQ (20%). Precision was acceptable if the intra- and
inter-day coefficients of variation (CV) were 20% or less
at the LOQ and 15% or less at all other concentrations.
LOQ was defined as the lowest concentration of the cali-
bration curve, which could be reliably differentiated from
background noise with a signal-to-noise ratio of at least
10:1 and quantified with acceptable accuracy (80 to 120%)
and precision (CV ≤ 20%); LOD was defined as the lowest
concentration that could be detected and reliably differ-
entiated from background noise with a signal-to-noise
ratio of at least 3:1.
The carry-over effect was tested by injecting regular
blank samples and ultrapure water into the high-perfor-
mance liquid chromatography system after high concen-
tration calibrators. Under the described chromatographic
conditions, piperacillin-tazobactam, ceftazidime,
cefepime, and meropenem were identified by sharp and
well-resolved peaks. The linearity was statistically con-
firmed over the concentration range tested for each β-
lactam and was associated with an r2 of more than 0.999.
The four analytical methods were accurate and precise.
LOD and LOQ were 0.50 and 0.75 μg/mL, respectively,
for piperacillin-tazobactam, 2.00 and 5.00 μg/mL for cef-
tazidime, and 0.07 and 0.10 μg/mL for cefepime and
meropenem. Appropriate dilution was performed for
clinical samples with concentrations above the upper
analytic range (corresponding to the calibration curve).
PK analysis
The PK of the four antibiotics was individually assessed
using WinNonlin Professional version 5.0.1. software
(Pharsight Corporation, Mountain View, CA, USA). A
one-compartment model with first-order elimination was
selected to fit the data. Investigated PK parameters
included maximal serum concentration (Cmax, calcu-
lated by extrapolation of the elimination phase at the end
of the infusion) Vd, total clearance (CL), elimination half-
live (t1/2) and area under the serum concentration-time
curve (AUC). V d and CL were normalized to the body
weight.
PK end-points
The threshold of MIC required for maximal β-lactam
activity is still controversial. In this study, the adequacy of
β-lactam therapy was assessed by calculating the time
spent greater than four times the target MIC (T > 4 ×
MIC). For each drug, the optimal T > 4 × MIC was con-
sidered as: above 50% for piperacillin-tazobactam, above
70% for ceftazidime and cefepime, and above 40% for
meropenem in Gram-negative bacterial infections [24].
As the dosage interval of β-lactams is prolonged in renal
impairment [see Additional file 1], we calculated the time
before the subsequent administration according to the
adjustment of the drug regimen to CrCl for each patient.
As there is a large variance in MIC values for different
bacteria, we considered the MICs for problematic patho-
gens, such as P. aeruginosa, commonly isolated in ICU
patients, as the empiric target threshold [25]. Sensitivity
thresholds of MIC for this pathogen, as defined by Euro-
pean Committee on Antimicrobial Susceptibility Testing
(EUCAST), are: 8 μg/mL or less (ceftazidime, cefepime),
16 μg/mL or less (piperacillin-tazobactam), and 2 μg/mL
or less (meropenem) [see Additional file 1] [26]. We,
therefore, classified each patient as having an 'adequate'
or 'inadequate' PK profile according to the percentage of
time during which serum drug concentrations remained
more than four times the clinical breakpoint for P. aerugi-
nosa (% T > 4 × MIC): 32 μg/mL or more (ceftazidime,
cefepime), 64 μg/mL or more (piperacillin-tazobactam),
and 8 μg/mL or more (meropenem). Finally, by simula-
tion using the PK parameters of our population, we calcu-
lated the probability of achieving target T > 4 × MIC
values for other MICs that can be found in ICU-isolated
Gram-negative bacteria.
Statistical analysis
Statistical analyses were performed using the SPSS 13.0
for Windows NT software package (SPSS Inc. 2004, Chi-Taccone et al. Critical Care 2010, 14:R126
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cago, IL, USA). Descriptive statistics were computed for
all study variables. A Kolmogorov-Smirnov test was used,
and histograms and normal-quantile plots were exam-
ined to verify the normality of distribution of continuous
variables. Discrete variables were expressed as counts
(percentage) and continuous variables as means ± stan-
dard deviation or median (25th to 75th percentiles).
Demographics and clinical differences between study
groups were assessed using a chi-squared, Fisher's exact
test, Student's t-test, or Mann-Whitney U test, as appro-
priate. The Pearson's (r) correlation coefficient was used
to determine linear correlation as appropriate. Associa-
tion between variables was tested by simple regression
analysis and coefficient of determination (R2) in case of
non-linear correlation. A P < 0.05 was considered as sta-
tistically significant.
Results
Patient characteristics
We enrolled 80 patients (mean age 63 years, 64% male;
Table 1) in the current study. Fifty-five (69%) of the
patients were medical admissions and 55 had a hospital
or ICU-acquired infection; 58 (72%) had septic shock.
The median APACHE II score was 22 and the median
SOFA score on admission was 8. Fifty-seven patients
(71%) were treated with mechanical ventilation; 22
patients (27%) had acute renal failure. Overall ICU mor-
tality was 38%, mostly due to sepsis. Most infections were
respiratory or abdominal and were microbiologically doc-
umented in 56 patients (70%). Blood cultures were posi-
tive in 32 patients (40%). Forty (50%) cases of sepsis were
secondary to Gram-negative bacilli, with 36 infections
due to difficult-to-treat pathogens (P. aeruginosa (n = 18);
Enterobacter species (n = 11); Citrobacter freundii, Haf-
nia alvei and Morganella morganii (n = 2 for each); Serra-
tia marcescens (n = 1)).
Pharmacokinetic data
Of the 80 patients, 16 were treated with meropenem, 18
with ceftazidime, 19 with cefepime, and 27 with pipera-
cillin-tazobactam. The mean PK parameters for the four
drugs are shown in Table 2. There was marked inter-indi-
vidual variation in all PK parameters; Vd was increased
for all four drugs when compared with healthy volun-
teers, with consequently a lower Cmax [see Additional
file 1]. The median total CL was also reduced when com-
pared with the median CL in healthy volunteers. The
median percentage of T > 4 × MIC was 57% for mero-
penem, 45% for ceftazidime, 34% for cefepime, and 33%
for piperacillin-tazobactam (Table 3). Thirteen patients
had plasma concentrations less than four times the target
MIC after only 90 minutes (ceftazidime = 1; cefepime = 1;
piperacillin-tazobactam = 11). The number of patients
who attained the target percentage T > 4 × MIC was 12 of
16 for meropenem (75%), 5 of 18 for ceftazidime (28%), 3
of 19 (16%) for cefepime, and 12 of 27 (44%) for piperacil-
lin-tazobactam.
Drug regimens were adapted because of renal impair-
ment in 41 patients (6 treated with meropenem, 9 with
ceftazidime, 12 with cefepime, and 14 with piperacillin-
tazobactam). The CrCl was similar among the four
groups (piperacillin-tazobactam 56 (ranges: 13 to 164)
mL/min; meropenem 64 (22 to 134) mL/min; ceftazidime
58 (15 to 145) mL/min; cefepime 40 (13 to 150) mL/min).
In patients with renal dysfunction (CrCl <50 mL/min), 5
of 6 (83%) attained the target concentration for mero-
penem, 3 of 9 (33%) for ceftazidime, 2 of 12 (17%) for
cefepime, and 10 of 14 (71%) for piperacillin-tazobactam.
For piperacillin-tazobactam, but not for the other antibi-
otics, patients with renal dysfunction had a significantly
higher probability of having adequate drug concentra-
Table 1: Characteristics, hemodynamic and biological data 
on admission and fluid balance during the first 24 hours (n 
= 80)
Age (years) 63 ± 13
Male/female 51/29
Body mass index 24.8 ± 4.8
APACHE II on admission 22 (18-28)
SOFA on admission 8 (5-10)
Medical/surgical 55/25
COPD 15 (19%)
Diabetes 21 (26%)
Heart disease 30 (38%)
Chronic renal insufficiency 7 (9%)
Liver cirrhosis 12 (15%)
Immunosuppressive drugs 26 (33%)
Malignancy 26 (33%)
Community/hospital 
infections
25/55
Severe sepsis/septic shock 22/58
Mechanical ventilation 57 (71%)
Acute renal failure 22 (27%)
ICU stay (days) 12 (5-25)
Overall ICU mortality 30 (38%)
Fluid balance (mL/24 h) 2559 ± 2010
Mean IN (mL/24 h) 4449 ± 1877
Mean OUT (mL/24 h) 1890 ± 1538
Data are expressed as counts (percentage), median (interquartile 
range) or mean ± standard deviation.
APACHE, Acute Physiology and Chronic Health Evaluation; COPD, 
Chronic obstructive pulmonary disease; SOFA, Sequential Organ 
Failure Assessment.Taccone et al. Critical Care 2010, 14:R126
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tions than patients with normal renal function (10 of 14
vs. 2 of 13, P = 0.03). Calculating the probability of target
T > 4 × MIC attainment for several MICs, values more
than 90% were obtained for ceftazidime and piperacillin-
tazobactam with MIC of 2 μg/mL or less and for cefepime
and meropenem with MIC of 1 μg/mL or less (Table 4).
Correlation with clinical variables
No correlation was found between the T > 4 × MIC and
any hemodynamic or clinical variable for any of the four
drugs, including age, mechanical ventilation, APACHE II
or SOFA score at admission, presence of shock, maxi-
mum dose of vasopressor agents or fluid balance. There
was a significant correlation between CrCl at admission
and CL for all drugs (data not shown).
Discussion
In this study, we show that current standard first doses of
piperacillin-tazobactam, cefepime and ceftazidime are
insufficient to maintain therapeutic serum concentra-
tions greater than four times the MIC of P. aeruginosa in
patients with severe sepsis and septic shock. Only with
meropenem did a large percentage of patients achieve the
bactericidal target of at least 40% T > 4 × MIC. Neverthe-
less, the probability of reaching the target concentration
was greater than 90% only for MICs of 1 μg/mL or less for
cefepime, and MICs of 2 μg/mL or less for ceftazidime
and piperacillin-tazobactam, suggesting that, for all these
drugs, insufficient drug concentrations are obtained for
pathogens with higher MICs.
Broad spectrum β-lactams are active against most
organisms recovered from ICU patients. Because of the
emergence of multidrug-resistant strains and the lack of
new antibiotics effective against Gram-negative bacteria
[27], a more effective use of existing therapies is neces-
sary. In vivo animal studies have demonstrated that β-lac-
tams have a slow continuous kill characteristic that is
almost entirely related to the time during which concen-
trations in tissue and serum exceed the MIC (T > MIC)
for the infecting organism [28,29]. The time above the
MIC required for maximal β-lactam activity may differ
depending on the drug as well as on the pathogen [24]. It
has been proposed that, in the absence of post-antibiotic
effects, the serum concentration of a β-lactam should
exceed the MIC for the respective organism for 100% of
the dosing interval [30]. However, experimental studies
have suggested that maximum killing of bacteria occurs
when β-lactam concentrations exceed four to five times
the MIC of the infecting pathogen for extended periods
Table 2: Pharmacokinetic parameters of the β-lactams
Vd (L/kg) Cmax (μg/mL) AUC (mg.h/mL) CL (mL/min.kg) t1/2 (hours)
Piperacillin-
tazobactam 
(n = 27)
0.38 (0.29-0.43) 123 (72-179) 469 (196-896) 2.02 (1.33-4.26) 2.58 (1.51-3.84)
Meropenem 
(n = 16)
0.43 (0.31-0.77) 35 (29-46) 132 (91-179) 1.87 (1.23-2.63) 2.05 (1.66-3.36)
Ceftazidime 
(n = 18)
0.48 (0.36-0.71) 63 (48-78) 522 (392-634) 0.89 (0.63-1.34) 5.84 (4.13-7.39)
Cefepime 
(n = 19)
0.36 (0.33-0.44) 68 (51-86) 310 (234-422) 1.26 (1.07-1.95) 3.37 (2.26-5.34)
Data are expressed as median [range].
AUC, area under the curve; CL, total clearance; Cmax, peak concentration; t1/2, elimination half-time; Vd, volume of distribution.
Table 3: Adequate concentrations of the four drugs, with regard to renal dysfunction
meropenem (n = 16) ceftazidime (n = 18) cefepime (n = 19) piperacillin-
tazobactam (n = 27)
T > 4 × MIC (%) 57 (25-100) 45 (8-100) 34 (10-100) 33 (0-100)
Adequate PK, n (%) 12 (75) 5 (28) 3 (16) 12 (44)
CrCl <50 mL/min (%) 5/6 (83) 3/9 (33) 2/12 (17) 10/14 (71)
CrCl >50 mL/min (%) 7/10 (70) 2/9 (22) 1/7 (14) 2/13 (15) *
Data are expressed as counts (percentage) or median (range).
CrCl, creatinine clearance; MIC, minimal inhibitory concentration; PK, pharmacokinetic.
* P = 0.03 (vs. CrCl < 50 mL/min).Taccone et al. Critical Care 2010, 14:R126
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[31,32]. For the treatment of infections in humans, opti-
mal β-lactam concentrations are still controversial. Clini-
cal confirmation of the PK parameters needed for
optimal β-lactam efficacy is limited because in several
studies drug levels were not measured and the patients
included had infections caused mostly by sensitive bacte-
ria [33]. In patients treated with cephalosporins, T > MIC
of 100% was associated with greater clinical cure and bac-
teriological eradication than T > MIC less than 100% [9].
However, the bactericidal activity of cephalosporins has
also been shown to be optimal at drug concentrations of
about four times the MIC [7]. Even if we preferred 4 ×
MIC as PK end-point in this study, we did not have
enough data to compare the efficacy of these two strate-
gies in the human setting, and a prospective study evalu-
ating the different β-lactams concentrations in the
treatment of severe infections is necessary.
Studies on serum concentrations of broad-spectrum β-
lactams have already reported that drug levels are insuffi-
cient in patients with severe infections. Cefepime (2 g
every 12 hours) concentrations were more than 70% T >
16 μg/mL in less than half the patients with sepsis [15]
and were adequate only for MICs of 4 μg/mL in all eight
patients suffering from post-operative infections [34].
Septic patients with normal renal function had serum
cefepime and ceftazidime levels less than 32 μg/mL after
a few hours in most cases [11,12]. Ceftazidime trough
concentrations were below the median MIC of P. aerugi-
nosa in more than half of the patients in another study
[35]. In only one study, ceftazidime levels were above the
MIC of the isolated pathogens for more than 90% of the
time interval; however Pseudomonas was isolated in only
4 of 16 patients [16]. Finally, piperacillin concentrations
were above therapeutic levels (64 μg/mL) for most of the
time interval in patients with sepsis [36] or nosocomial
pneumonia [37]. However, serum drug concentrations of
meropenem were adequate in most of the patients. In
severe infections associated with septicemia, mostly after
cardiac surgery, meropenem had serum concentrations
above 8 μg/mL for at least 50% of the time in patients
with normal and those with reduced CrCl [38]. In
patients with ventilator-associated pneumonia, mean T >
4 × MIC for Pseudomonas was reported as 52% in one
study [39] and 46% in another [17].
Nevertheless, most of these previous studies excluded
severely ill patients with septic shock and those with an
estimated CrCl limiting the generalization of their results
to other populations of critically ill patients. The number
of patients was also limited and analyses concerned only
the steady-state of the disease. Finally, some of these
studies used lower than recommended dosage regimens,
which are associated with an increased mortality when
susceptible pathogens with higher MICs are present
[40,41]. Our study focused on a more severe population
of patients, suffering from severe sepsis and septic shock,
with higher mortality and morbidity rates than less
severely ill ICU populations [42]. Importantly, we used
recommended β-lactam regimens that have the greatest
likelihood of achieving a bactericidal target in nosocomial
pneumonia and bloodstream infections due to Gram-
negative bacteria [43,44]. Finally, because antimicrobial
treatment of sepsis is often initiated empirically, when
pathogens and MICs are still unknown, we used as the
target MIC the clinical breakpoint defined by EUCAST
for P. aeruginosa, an organism that is commonly isolated
in ICUs and associated with high mortality rates [25].
This strategy could then be extrapolated to other 'diffi-
Table 4: Probability of target T >4 × MIC attainment for various MICs
Adequate PK N (%)
MIC (μg/mL) Target 
concentration 
(μg/mL)
meropenem 
(n = 16)
ceftazidime 
(n = 18)
cefepime (n = 19) piperacillin-
tazobactam 
(n = 27)
32 128 000 1  ( 4 )
16 64 00 1  ( 5 ) 12 (44)
83 20 5 (28) 3 (16) 15 (56)
41 6 3 (18) 14 (78) 7 (36) 21 (78)
2 8 12 (75) 18 (100) 15 (79) 25 (93)
14 15 (94) 18 (100) 17 (90) 27 (100)
0.5 2 16 (100) 18 (100) 19 (100) 27 (100)
Data are expressed as counts (percentage). In bold: MIC corresponding to European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) clinical breakpoints for Pseudomonas aeruginosa.
MIC, minimal inhibitory concentration; PK, pharmacok inetics.Taccone et al. Critical Care 2010, 14:R126
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cult-to-treat' pathogens with high susceptibility break-
points.
The consequences of these low antimicrobial levels may
be more cases of therapeutic failure, higher medical costs
and greater emergence of resistance [45]. Moreover, low
plasma levels can contribute to lower than expected β-
lactam concentrations in the extracellular [46], bronchial
[47] or peritoneal fluid [48] with potentially reduced anti-
microbial delivery to the target tissues. In view of these
results, in septic patients, broad-spectrum β-lactams
should be administered more frequently than suggested
in non-septic patients, or with doses larger than standard
regimens to optimize pathogen exposure to bactericidal
concentrations of the drugs. Population modeling simula-
tion showed that continuous or extended β-lactam infu-
sions are required to obtain adequate serum
concentrations [45]. However, clinical data that have
shown a better outcome using this strategy have come
just from retrospective studies in ICU populations with
pneumonia [49,50]. Further studies are needed in ICU
patients to assess the influence on morbidity and mortal-
ity of a strategy whereby antibiotic therapy is selected
based on the optimal PK, especially in patients with sep-
sis and in infections caused by multiresistant pathogens.
Although a relation between the intensity of the septic
process and PK abnormalities can be assumed, we did not
find any relation between T > 4 × MIC and any demo-
graphic, clinical, hemodynamic or biological variables.
This finding may be related to the fact that the PK analy-
ses were performed during the early phase of sepsis. Also,
as a first dose of antibiotic is largely influenced by Vd, the
increased distribution volume may play a key role in
reducing antimicrobial concentrations in this setting
whereas drug clearance remains the main determinant
f o r  d r u g  c o n c e n t r a t i o n s  a t  s t e a d y - s t a t e  [ 1 3 ] .  C r C l  a n d
drug CL showed good correlation, as elimination of the
studied drugs is largely dependent on glomerular func-
tion [11,38]. Nevertheless, despite a regimen adapted to
renal function, patients treated with piperacillin-tazobac-
tam had a higher percentage of adequate concentrations
when CrCl was below 50 mL/min. This finding may be
related to the complex elimination of piperacillin-
tazobactam, which includes biliary excretion [13].
Indeed, the hepatic metabolism of this drug is variable
and difficult to measure and most studies on piperacillin-
tazobactam PKs in patients with renal failure have
included patients with normal hepatic function [51]. It is
possible that, as severe sepsis is frequently associated
with liver dysfunction, this may have contributed to
greater than expected drug accumulation in some
patients. Further studies are needed to evaluate the
impact of renal and hepatic dysfunction on piperacillin-
tazobactam regimens in critically ill patients.
Our study has some limitations. First, we evaluated the
PK profile of β-lactams only during the first dose, and
thus cannot make any statement with regard to subse-
quent doses. Vd may decrease during therapy when capil-
lary leakage subsides and sepsis resolves [52]; in such
circumstances, coupled with persistent renal dysfunction,
standard β-lactam doses may be sufficient to achieve
therapeutic concentrations. Second, as only free drug is
the active moiety, it has been recommended that all PK/
pharmacodynamic indices should be referenced to the
unbound (free) fraction of the drug, especially for some
drugs such as piperacillin, which has 20 to 30% protein
binding [53]. Third, the inadequate PK/pharmacody-
namic indices observed in our study should be considered
in relation to the empirical MIC target, and may be differ-
ent with other susceptibility patterns (MIC distributions)
of pathogens at individual institutions. Attention should
therefore be paid to establish the MIC values of these
pathogens in order to adapt dosage regimens. Also, CrCl
was estimated using the Cockroft and Gault formula,
which shows important limitations in predicting the real
CrCl in ICU patients [54]. Finally, the four groups were
heterogeneous and, therefore, the numbers may be too
small to fully reflect the characteristics of the drugs in
this setting. However, an important concern is the highly
variable and unpredictable inter-individual PKs for
cephalosporins and piperacillin and whether these drugs
can be considered an appropriate agent to use as initial
empirical therapy for critically ill patients with severe
sepsis and septic shock, particularly in those with poten-
tially less susceptible Gram-negative bacterial strains.
Conclusions
The treatment of infections in the critically ill patient
remains a significant challenge for clinicians. Standard
first doses of broad-spectrum β-lactams provided inade-
quate levels to achieve target serum concentrations for
extended periods of time in critically ill patients with sep-
sis. Improved characterization of the pharmacodynamic
properties of these antimicrobials may lead to revisions in
recommendations on dosing in severe infections, espe-
cially in the early phase of severe sepsis and septic shock.
Key messages
• Recommended doses of piperacillin-tazobactam, 
cefepime and ceftazidime provided serum drug con-
centrations during the first 24 hours of treatment that 
were insufficient to cover P. aeruginosa and other less 
susceptible bacteria in patients suffering from severe 
sepsis and septic shock.
• Recommended doses of meropenem resulted in 
adequate concentrations to cover P. aeruginosa and 
other less susceptible bacteria in 75% of patients.Taccone et al. Critical Care 2010, 14:R126
http://ccforum.com/content/14/4/R126
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• In patients treated with piperacillin-tazobactam, 
renal dysfunction is associated with a better adequacy 
of drug concentrations compared with normal renal 
function.
• Therapeutic drug monitoring is necessary to opti-
mize β-lactam concentrations as no clinical or biolog-
ical variable can predict β-lactam concentrations in 
this population.
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